Olaf H Klungel

List of Publications by Year
in descending order

124 papers	4,090 citations	186265 28 h-index	133252 59 g-index
127 all docs	127 docs citations	127 times ranked	8431 citing authors

#	Article	IF	Citations
1	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet, The, 2015, 385, 351-361.	13.7	562
2	Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ, The, 2014, 349, g4164-g4164.	6.0	528
3	The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ: British Medical Journal, 2018, 363, k3532.	2.3	268
4	Reporting of covariate selection and balance assessment in propensity score analysis is suboptimal: a systematic review. Journal of Clinical Epidemiology, 2015, 68, 122-131.	5.0	221
5	Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc RiskÂScoresÂPredicting Stroke in PatientsÂWithÂAtrial Fibrillation. Journal of the American College of Cardiology, 2015, 66, 1851-1859.	2.8	162
6	Increased Bleeding Risk With Concurrent Use of Selective Serotonin Reuptake Inhibitors and Coumarins. Archives of Internal Medicine, 2008, 168, 180.	3.8	127
7	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. Pharmacoepidemiology and Drug Safety, 2017, 26, 1018-1032.	1.9	126
8	Secretory Phospholipase A2-IIA and Cardiovascular Disease. Journal of the American College of Cardiology, 2013, 62, 1966-1976.	2.8	115
9	Defining the noninferiority margin and analysing noninferiority: An overview. British Journal of Clinical Pharmacology, 2017, 83, 1636-1642.	2.4	113
10	Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a crossâ€national descriptive study from the PROTECTâ€EU Project. Pharmacoepidemiology and Drug Safety, 2016, 25, 56-65.	1.9	96
11	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. Value in Health, 2017, 20, 1009-1022.	0.3	70
12	Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies. Pharmacoeconomics, 2018, 36, 359-368.	3.3	67
13	Challenges in Advanced Therapy Medicinal Product Development: A Survey among Companies in Europe. Molecular Therapy - Methods and Clinical Development, 2018, 11, 121-130.	4.1	63
14	Methods of defining the non-inferiority margin in randomized, double-blind controlled trials: a systematic review. Trials, 2017, 18, 107.	1.6	56
15	Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2017, 11, 175-184.	1.3	52
16	Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands. Scientific Reports, 2021, 11, 6306.	3.3	48
17	Prevalence of antibiotic use: a comparison across various European health care data sources. Pharmacoepidemiology and Drug Safety, 2016, 25, 11-20.	1.9	46
18	Exploring interaction effects in small samples increases rates of false-positive and false-negative findings: results from a systematic review and simulation study. Journal of Clinical Epidemiology, 2014, 67, 821-829.	5.0	44

#	Article	IF	Citations
19	Best (but oft-forgotten) practices: propensity score methods in clinical nutrition research. American Journal of Clinical Nutrition, 2016, 104, 247-258.	4.7	42
20	Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008â€"2015): A crossâ€national drug utilization study. British Journal of Clinical Pharmacology, 2019, 85, 2524-2539.	2.4	41
21	Methods to control for unmeasured confounding in pharmacoepidemiology: an overview. International Journal of Clinical Pharmacy, 2016, 38, 714-23.	2.1	40
22	Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, f72-f80.	3.0	37
23	Multiâ€centre, multiâ€database studies with common protocols: lessons learnt from the IMI PROTECT project. Pharmacoepidemiology and Drug Safety, 2016, 25, 156-165.	1.9	36
24	Considerations for pharmacoepidemiological analyses in the <scp>SARSâ€CoV</scp>â€2 pandemic. Pharmacoepidemiology and Drug Safety, 2020, 29, 825-831.	1.9	36
25	Antiepileptic drug use in seven electronic health record databases in Europe: A methodologic comparison. Epilepsia, 2014, 55, 666-673.	5.1	35
26	Systematic evaluation of the efficacyâ€"effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer. European Respiratory Journal, 2018, 52, 1801100.	6.7	34
27	Impact of opioids on P2Y12 receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 4-12.	3.0	34
28	What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings. Cytotherapy, 2020, 22, 388-397.	0.7	29
29	Association Between Statin Use and Lupus-Like Syndrome Using Spontaneous Reports. Seminars in Arthritis and Rheumatism, 2011, 41, 373-381.	3.4	28
30	How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias. Pharmacoepidemiology and Drug Safety, 2020, 29, 3-7.	1.9	28
31	Statin-Associated Polymyalgia Rheumatica. An Analysis Using WHO Global Individual Case Safety Database: A Case/Non-Case Approach. PLoS ONE, 2012, 7, e41289.	2.5	27
32	Risk of Nephrotic Syndrome for Non-Steroidal Anti-Inflammatory Drug Users. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1355-1362.	4.5	27
33	The impact of age and sex on the reporting of cough and angioedema with reninâ€"angiotensin system inhibitors: a case/noncase study in VigiBase. Fundamental and Clinical Pharmacology, 2017, 31, 676-684.	1.9	25
34	Methodological comparison of marginal structural model, timeâ€varying Cox regression, and propensity score methods: the example of antidepressant use and the risk of hip fracture. Pharmacoepidemiology and Drug Safety, 2016, 25, 114-121.	1.9	24
35	Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries. Europace, 2021, 23, 1722-1730.	1.7	24
36	Justification of exclusion criteria was underreported in a review of cardiovascular trials. Journal of Clinical Epidemiology, 2014, 67, 635-644.	5.0	23

#	Article	IF	Citations
37	Understanding inconsistency in the results from observational pharmacoepidemiological studies: the case of antidepressant use and risk of hip/femur fractures. Pharmacoepidemiology and Drug Safety, 2016, 25, 88-102.	1.9	23
38	Gastrointestinal toxicity among patients taking selective COX-2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case-control study. Pharmacoepidemiology and Drug Safety, 2017, 26, 1141-1148.	1.9	23
39	More Dose-dependent Side Effects with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher Dosing. Inflammatory Bowel Diseases, 2017, 23, 1873-1881.	1.9	23
40	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. Circulation Genomic and Precision Medicine, 2019, 12, e002471.	3.6	22
41	Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study. European Heart Journal, 2022, 43, 3528-3538.	2.2	22
42	Statins accelerate the onset of collagen type II-induced arthritis in mice. Arthritis Research and Therapy, 2012, 14, R90.	3.5	20
43	The IMI PROTECT project: purpose, organizational structure, and procedures. Pharmacoepidemiology and Drug Safety, 2016, 25, 5-10.	1.9	20
44	Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation. British Journal of Clinical Pharmacology, 2021, 87, 988-1000.	2.4	19
45	Comparative effectiveness of recommended versus less intensive drug combinations in secondary prevention of acute coronary syndrome. Pharmacoepidemiology and Drug Safety, 2017, 26, 285-293.	1.9	18
46	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. Circulation Genomic and Precision Medicine, 2019, 12, e002470.	3.6	17
47	Global covid-19 vaccine rollout and safety surveillance—how to keep pace. BMJ, The, 2021, 373, n1416.	6.0	17
48	Major bleeding in users of direct oral anticoagulants in atrial fibrillation: A pooled analysis of results from multiple population‐based cohort studies. Pharmacoepidemiology and Drug Safety, 2021, 30, 1339-1352.	1.9	17
49	Risk of acute liver injury associated with use of antibiotics. Comparative cohort and nested case–control studies using two primary care databases in Europe. Pharmacoepidemiology and Drug Safety, 2016, 25, 29-38.	1.9	16
50	Left truncation results in substantial bias of the relation between time-dependent exposures and adverse events. Annals of Epidemiology, 2015, 25, 590-596.	1.9	15
51	Association of preceding antithrombotic therapy in atrial fibrillation patients with ischaemic stroke, intracranial haemorrhage, or gastrointestinal bleed and mortality. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 3-10.	3.0	15
52	A Review of Methodological Considerations for Economic Evaluations of Gene Therapies and Their Application in Literature. Value in Health, 2020, 23, 1268-1280.	0.3	14
53	Application of Healthcare 'Big Data' in CNS Drug Research: The Example of the Neurological and mental health Global Epidemiology Network (NeuroGEN). CNS Drugs, 2020, 34, 897-913.	5.9	14
54	Pattern of risks of rheumatoid arthritis among patients using statins: A cohort study with the clinical practice research datalink. PLoS ONE, 2018, 13, e0193297.	2.5	14

#	Article	IF	Citations
55	Pattern of risks of systemic lupus erythematosus among statin users: a population-based cohort study. Annals of the Rheumatic Diseases, 2017, 76, 1723-1730.	0.9	13
56	Social media as a tool for assessing patient perspectives on quality of life in metastatic melanoma: a feasibility study. Health and Quality of Life Outcomes, 2018, 16, 222.	2.4	13
57	Do caseâ€only designs yield consistent results across design and different databases? A case study of hip fractures and benzodiazepines. Pharmacoepidemiology and Drug Safety, 2016, 25, 79-87.	1.9	12
58	Impact of varying outcomes and definitions of suicidality on the associations of antiepileptic drugs and suicidality: comparisons from <scp>UK Clinical Practice Research Datalink (CPRD)</scp> and <scp>Danish</scp> national registries (DNR). Pharmacoepidemiology and Drug Safety, 2016, 25, 142-155.	1.9	12
59	Postauthorization Changes to Specific Obligations of Conditionally Authorized Medicines in the European Union: AÂRetrospective Cohort Study. Clinical Pharmacology and Therapeutics, 2019, 105, 426-435.	4.7	12
60	Conditional Financing of Drugs in the Netherlands: Past, Present, and Futureâ€"Results From Stakeholder Interviews. Value in Health, 2019, 22, 399-407.	0.3	12
61	Estimation of manufacturing development costs of cell-based therapies: a feasibility study. Cytotherapy, 2021, 23, 730-739.	0.7	12
62	Giant Cell Arteritis and Polymyalgia Rheumatica After Reexposure to a Statin: A Case Report. Annals of Internal Medicine, 2014, 161, 614.	3.9	11
63	Caseâ€only designs for studying the association of antidepressants and hip or femur fracture. Pharmacoepidemiology and Drug Safety, 2016, 25, 103-113.	1.9	11
64	Evaluating different physician's prescribing preference based instrumental variables in two primary care databases: a study of inhaled longâ€acting beta2â€agonist use and the risk of myocardial infarction. Pharmacoepidemiology and Drug Safety, 2016, 25, 132-141.	1.9	11
65	Association of Factor V Leiden With Subsequent Atherothrombotic Events. Circulation, 2020, 142, 546-555.	1.6	11
66	Drug exposure misclassification in pharmacoepidemiology: Sources and relative impact. Pharmacoepidemiology and Drug Safety, 2021, 30, 1703-1715.	1.9	11
67	Time Trends of Period Prevalence Rates of Patients with Inhaled Long-Acting Beta-2-Agonists-Containing Prescriptions: A European Comparative Database Study. PLoS ONE, 2015, 10, e0117628.	2.5	11
68	Utilisation and Off-Label Prescriptions of Respiratory Drugs in Children. PLoS ONE, 2014, 9, e105110.	2.5	10
69	Patientsâ€™ beliefs about medicine are associated with early thiopurine discontinuation in patients with inflammatory bowel diseases. European Journal of Gastroenterology and Hepatology, 2018, 30, 167-173.	1.6	10
70	Exploring the role of low-frequency and rare exonic variants in alcohol and tobacco use. Drug and Alcohol Dependence, 2018, 188, 94-101.	3.2	10
71	Concomitant Anticoagulant and Antidepressant Therapy in Atrial Fibrillation Patients and Risk of Stroke and Bleeding. Clinical Pharmacology and Therapeutics, 2020, 107, 287-294.	4.7	10
72	A systematic review of how missing data are handled and reported in <scp>multiâ€database</scp> pharmacoepidemiologic studies. Pharmacoepidemiology and Drug Safety, 2021, 30, 819-826.	1.9	10

#	Article	IF	Citations
73	Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies. Clinical and Translational Science, 2021, 14, 1566-1577.	3.1	10
74	Thiazolidinediones and Glucagonâ€Like Peptideâ€1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study. Hepatology, 2021, 74, 2467-2477.	7.3	10
75	Incidence, hospitalization and mortality and their changes over time in people with a first ever diabetic foot ulcer. Diabetic Medicine, 2022, 39, e14725.	2.3	10
76	Greedy caliper propensity score matching can yield variable estimates of the treatmentâ€outcome associationâ€"A simulation study. Pharmacoepidemiology and Drug Safety, 2021, 30, 934-951.	1.9	9
77	Unmeasured confounding in pharmacoepidemiology. Annals of Epidemiology, 2016, 26, 85-86.	1.9	8
78	The impact of serum potassiumâ€influencing antihypertensive drugs on the risk of outâ€ofâ€hospital cardiac arrest: A caseâ€"control study. British Journal of Clinical Pharmacology, 2017, 83, 2541-2548.	2.4	8
79	Risk of a firstâ€ever acute myocardial infarction and allâ€cause mortality with sulphonylurea treatment: A populationâ€based cohort study. Diabetes, Obesity and Metabolism, 2018, 20, 1056-1060.	4.4	8
80	Accuracy of budget impact estimations and impact on patient access: a hepatitis C case study. European Journal of Health Economics, 2019, 20, 857-867.	2.8	8
81	Use of Sodium-Glucose Co-Transporter-2-Inhibitors (SGLT2-Is) and Risk of Lower Limb Amputation. Current Drug Safety, 2021, 16, 62-72.	0.6	8
82	The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs. International Journal of Health Policy and Management, 2020, , .	0.9	8
83	The risk of acute liver injury among users of antibiotic medications: a comparison of caseâ€only studies.. Pharmacoepidemiology and Drug Safety, 2016, 25, 39-46.	1.9	7
84	Patterns of antiplatelet drug use after a first myocardial infarction during a 10â€year period. British Journal of Clinical Pharmacology, 2017, 83, 632-641.	2.4	7
85	Risk of myocardial infarction associated with nonâ€steroidal antiâ€inflammatory drugs: Impact of additional confounding control for variables collected from selfâ€reported data. Journal of Clinical Pharmacy and Therapeutics, 2019, 44, 623-631.	1.5	7
86	Non-vitamin K antagonist oral anticoagulants, proton pump inhibitors and gastrointestinal bleeds. Heart, 2022, 108, 613-618.	2.9	7
87	Strengthening international surveillance of vaccine safety. BMJ, The, 2021, 374, n1994.	6.0	7
88	Risk patterns in drug safety study using relative times by accelerated failure time models when proportional hazards assumption is questionable: an illustrative case study of cancer risk of patients on glucoseâ€lowering therapies. Pharmaceutical Statistics, 2015, 14, 382-394.	1.3	6
89	Instrumental variables analysis using multiple databases: an example of antidepressant use and risk of hip fracture. Pharmacoepidemiology and Drug Safety, 2016, 25, 122-131.	1.9	6
90	Medications Recommended for Secondary Prevention After First Acute Coronary Syndrome: Effectiveness of Treatment Combinations in a Realâ€Life Setting. Clinical Pharmacology and Therapeutics, 2018, 103, 1038-1046.	4.7	6

#	Article	IF	Citations
91	Sex differences in the medication choice for hypertension in general practice. A study with written case simulations. International Journal of Clinical Pharmacy, 2000, 22, 140-146.	1.4	5
92	Cyclo‑oxygenase selectivity and chemical groups of nonsteroidal anti‑inflammatory drugs and the frequency of reporting hypersensitivity reactions: a case/noncase study in VigiBase. Fundamental and Clinical Pharmacology, 2019, 33, 589-600.	1.9	5
93	Development and Regulation of Gene and Cell-Based Therapies in Europe: A Quantification and Reflection. Trends in Pharmacological Sciences, 2020, 41, 67-71.	8.7	5
94	Pre‑approval and post‑approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs. British Journal of Clinical Pharmacology, 2022, 88, 2169-2179.	2.4	5
95	Bayesian methods including nonrandomized study data increased the efficiency of postlaunch RCTs. Journal of Clinical Epidemiology, 2015, 68, 387-396.	5.0	4
96	Using a single noninferiority margin or preserved fraction for an entire pharmacological class was found to be inappropriate. Journal of Clinical Epidemiology, 2018, 104, 15-23.	5.0	4
97	Quality of reporting of drug exposure in pharmacoepidemiological studies. Pharmacoepidemiology and Drug Safety, 2020, 29, 1141-1150.	1.9	4
98	Disparities in model-based cost-effectiveness analyses of tuberculosis diagnosis: A systematic review. PLoS ONE, 2018, 13, e0193293.	2.5	3
99	Assessment of the Regulatory Dialogue Between Pharmaceutical Companies and the European Medicines Agency on the Choice of Noninferiority Margins. Clinical Therapeutics, 2020, 42, 1588-1594.	2.5	3
100	Prescribers' compliance with summary of product characteristics of dabigatran, rivaroxaban and apixaban‑A European comparative drug utilization study. Basic and Clinical Pharmacology and Toxicology, 2021, 128, 440-454.	2.5	3
101	Systematic evaluation of the efficacy‑effectiveness gap of systemic treatments in extensive disease small cell lung cancer. Pharmacoepidemiology and Drug Safety, 2021, 30, 445-450.	1.9	3
102	Comprehensive evaluation of post-approval regulatory actions during the drug lifecycle – a focus on benefits and risks. Expert Opinion on Drug Safety, 2021, 20, 1-10.	2.4	3
103	Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors. Cancer Epidemiology, 2022, 78, 102149.	1.9	3
104	Mapping the risk of infections in patients with multiple sclerosis: A multi-database study in the United Kingdom Clinical Practice Research Datalink GOLD and Aurum. Multiple Sclerosis Journal, 2022, 28, 1808-1818.	3.0	3
105	Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions. Pharmacoepidemiology and Drug Safety, 2019, 28, 1563-1571.	1.9	2
106	The International Society for Pharmacoepidemiology's Comments on the Core Recommendations in the Summary of the Heads of Medicines Agencies (HMA) ‑EMA Joint Big Data Task Force. Pharmacoepidemiology and Drug Safety, 2019, 28, 1640-1641.	1.9	2
107	Impact of the definition of osteoarthritis and of the timing of its onset on the association between type 2 diabetes mellitus and osteoarthritis: Clinical Practice Research Datalink. Diabetes Research and Clinical Practice, 2019, 148, 240-248.	2.8	2
108	Effect of CYP3A4*22 and PPAR-α Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention. Genes, 2020, 11, 1068.	2.4	2

#	ARTICLE	IF	CITATIONS
109	Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study. Pharmacoepidemiology and Drug Safety, 2020, 29, 1263-1272.	1.9	2
110	Increasing the information provided by probabilistic sensitivity analysis: The relative density plot. Cost Effectiveness and Resource Allocation, 2020, 18, 54.	1.5	2
111	Non-steroidal anti-inflammatory drugs and the risk of out-of-hospital cardiac arrest: a case–control study. Europace, 2019, 21, 99-105.	1.7	1
112	Managing Uncertainties Due to Limited Evidence in Economic Evaluations of Novel Anti-Tuberculosis Regimens: A Systematic Review. PharmacoEconomics - Open, 2020, 4, 223-233.	1.8	1
113	Affordability of oncology drugs: accuracy of budget impact estimations. Journal of Market Access & Health Policy, 2020, 8, 1697558.	1.5	1
114	A novel method for predicting the budget impact of innovative medicines: validation study for oncolytics. European Journal of Health Economics, 2020, 21, 845-853.	2.8	1
115	Response to: Kumar N, Ahmed M. Letter to the editor in response to Komen et al. 2021. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e31-e31.	3.0	1
116	Impact of anticoagulant exposure misclassification on the bleeding risk of direct oral anticoagulants. British Journal of Clinical Pharmacology, 2021, 87, 3508-3517.	2.4	1
117	Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in extensive disease small cell lung cancer (ED SCLC). , 2019, , .		1
118	Challenges in the Design, Registration, and Reporting of Noninferiority Trials. JAMA Psychiatry, 2022, 79, 191.	11.0	1
119	The neurological safety of covid-19 vaccines. BMJ, The, 2022, 376, o522.	6.0	1
120	Pharmacoepidemiological Approaches for Population-Based Hypothesis Testing. Methods in Pharmacology and Toxicology, 2018, , 201-216.	0.2	0
121	Effect of metabolic genetic variants on long-term disease comorbidity in patients with type 2 diabetes. Scientific Reports, 2021, 11, 2794.	3.3	0
122	Determinants of treatment modification before and after implementation of the updated 2015 NICE guideline on type 2 diabetes: A retrospective cohort study. Diabetes Research and Clinical Practice, 2021, 176, 108828.	2.8	0
123	Impact of vomiting on P2Y12 platelet inhibition in patients with ST-elevation myocardial infarction: A prespecified subanalysis of the ON-TIME 3 trial. American Heart Journal, 2022, 243, 39-42.	2.7	0
124	Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer (ED SCLC). , 2019, , .		0